Press Room

Speech during the Chinese Banquet at the Hyatt Hotel to celebrate the inauguration of Building 2A in Macau on the 9th November 2001   Dear Friends, Today we had the visit of the Macau Chief executive to mark the opening of the new facilities. This was a major effort and an investment of over $14m, we are all very pleased, but let me tell you how it all started. An email dated 5th October, read as follows: This is to advise the results of the competition of ideas; the decision of the jury was made public at a celebratory dinner on the 2nd October 1998. This was held at the Grémio Literário Club in Lisbon, the prizes were presented by Noé Carreira, José Rato and Guy Villax - members of the jury (Ivan Villax and Carlos Costa, also members of the jury, were not present). The results were: Joint 1st Prize: Alfred Nobel - Jorge Pastilha Lavoisier - Alexandre Carvalho   Joint 3rd Prize: Baeyer Team - Terry, Eddy, Leong, Eric, Boli Pasteur - José Lisboa   The awarded prizes were: for each of the first prizes: about MOP45.000 in cash and a trip to Macau to see the new plant. for each of the third prizes: a trip to Macau to see the new plant for José Lisboa and a trip to Lisbon for each of the Baeyer team members to see chemical plants in Europe1. The 4 documents will be copied and made available internally - you can get a copy at the Human Resources Department. The Jury extends its thanks and congratulations to all participants; the ideas gathered during the competition were very valuable and are a great contribution to the design of new installations. Back in 1998 Hovione had just started up B15, its new automated plant in Loures with a technically challenging new project, which would turn into Hovione’s biggest ever product. We had just passed an FDA inspection; we could have decided to become complacent and pleased with ourselves – we did not. We felt that our plant design could be improved – we were looking for more flexibility, quicker change-over-time, better compliance by design – a plant that would give us better quality, better yields and better profits. So that summer we opened a competition for the best idea for a new API plant. The people at Hovione had another challenge. Today, this opening, is exclusively a tribute to Hovione people and to their sense of engineering and creativity, their ability to design, plan and implement, to work as a multidisciplinary team in a multicultural environment and to manage a project that is designed in Portugal and made reality in Macau. The achievement observed tough constraints: Full compliance with the toughest standards (FDA, ICH, ISPE); Strict concern for minimal expenditure. Let me tell you about the project: Building 2A: we doubled the plant’s manufacturing capacity by adding 40m3 of reactors and 2 finishing lines with centrifuges/driers and packing rooms (class 100.000). All equipment is modular (identically and fully equipped) and totally flexible with the ability of interconnection in all situations. Separate sets of vents and vacuum lines enable the running of two separate products simultaneously with impossibility of cross- contamination. All equipment is connected to a DCS automation system; Buildings 7A and 4: we doubled all the utilities (mono-fluid system for heating and cooling, solvent storage, etc.); Building 11: we doubled the office space, and maintenance workshops; Building 9: we renovated the old fire-cracker factory stone house and turned into our canteen and social area, this is set in a Chinese garden set in the middle of large, century old, banyan trees. Budgets and timelines: We have invested MOP120m investment (US$15m), overall we were 20% over budget; From License application to start-up 24 months elapsed. Lessons: Improve our planning and project management skills; Allow more time to plan, design and review design critically – this might increase slightly project time, but it will allow us to be in budget (better purchasing and better planning), do a better job right-first-time and have less pressure and stress; Allow for more resources in the planning, controlling and project information function. And to give glory, where glory is due, I must tell you that this project was the first one to be totally delegated to a project team of young in-house professionals. Noé Carreira, our Chief Engineer for 20 years was the project sponsor, and had an oversight role – otherwise the project team had “carte blanche” to design and implement what their training and career experience at Hovione told them was best: suited to our clients’ products, suited to difficult chemistries, flexible, compliant, engineered for quick-change-over and capable of earning profits while keeping our prices totally competitive, and our ability to being “always available” for the customer. I do mean “carte blanche”, both in terms of design and how the funds were spent. My control over this project consisted on: signoff of the project baseline requirements and of the initial budget, and three visits to Macau. Somehow I am amazed at the ambition and the high standards the Project Team set for the “ideal plant”, the high level of investment it decided upon, the degree of sophistication in the automation, the ventilation, the CIP and product containment systems – the extensive use of hastelloy and stainless steel – and yet I authorized it and I trust the best judgment of the team; and I am sure this is the ideal plant. Over the coming 2 years we shall confirm this, and use your knowledge and experience to build more plants. The stubbornness of the project team is to be commended! It may have led to some spurts of fury on my part, however on reflection no project manager could have achieved this exploit without the firmest belief in what he/she was doing the right thing. I can imagine there have been some difficult moments, great pressures and too much constant stress. Yet I know that being involved in such a project is a terrific feeling, and the achievement of a job well done is worth everything. I know, I was here 15 years ago when we built the first phase of this plant. Thank you for your efforts, and congratulations for your achievements – you can all be proud of yourselves and of your work. Guy Villax Chief Executive Macau, 9th November 2001     1 As part of their European factories tour the Baeyer Team was kindly welcomed in Germany by Bayer, who organized visits in Kiel, Wuppertahl, Monheim and Leverkusen. The Baeyer team was made up of 5 plant operators (Eric Ng would seem to have had an undeclared leadership role… Eric today heads Safety and Warehouse services).

Press Release
Speech during the Chinese Banquet at the Hyatt Hotel

Address by the CEO on the inauguration of Building 2A in Macau

Nov 09, 2001

Lisbon, Nov. 5 (Bloomberg) -- Hovione FarmaCiencia SA is using one of its oldest products to fight the world's newest terrorist threat. The Portuguese company makes doxycycline, an antibiotic that U.S. authorities are increasingly choosing to treat anthrax over Bayer AG's more expensive Cipro, which they used after the initial cases of exposure to the potentially deadly bacteria. After almost 20 years of selling doxycycline to treat respiratory disorders, sexually transmitted diseases, even an outbreak of plague in India, Hovione says it's able to quickly boost production to meet the increased demand. In fact, it's done so before. ``Ten years ago, before Desert Storm, it was exactly the same situation,'' Chief Executive Officer Guy Villax said in an interview. ``Every soldier that went to Desert Storm had their doses of doxycycline in anticipation for bio-warfare,'' and soldiers who went to Somalia did the same. ``Whenever there's this type of emergency, we have to find solutions,'' he said. Web Site Hovione says it accounts for about 75 percent of the U.S. market for doxycycline, a generic drug. The family-controlled chemicals company exports the active ingredient for doxycycline to companies in the U.S. and about 30 other countries that put the ingredient into pills. The company started preparing to boost production when it received a surge in hits on its Web page about doxycycline, soon after the Sept. 11 terrorist attacks, as people anticipated the possibility of bio-terrorism. ``We got our act together in terms of reorganizing production, redefining priorities, getting in touch with our raw-materials suppliers to put the supply chains in place,'' Villax said. Hovione makes doxycycline at its plant in Macau, the former Portuguese colony governed by China since 1999. Hovione's near Lisbon boasts two Chinese statues of lions at the gates. The Portugal plant may pitch in to meet the increased demand, Villax said. Demand Peaks The U.S. government is ordering enough doxycycline to treat 20 million people for 60 days, Villax said. ``We know we are facing a peak in demand because of all this stockpiling,'' he added. ``We can produce large quantities very fast, but I cannot imagine that this rush is going to last beyond (the first quarter) of next year, and by that time there will be ample stocks and the concern with shortage will disappear.'' Besides costing about one fourth as much as Cipro, doxycycline is gaining acceptance as a safer drug for dealing with anthrax, with fewer side effects. After a report by the U.S. Centers for Disease Control last month recommended the use of doxycycline, officials in Washington who had provided Cipro to thousands of postal and government workers switched to the generic drug. Doxycycline accounts for less than 10 percent of Hovione's annual sales of about $70 million, Villax said. ``It's an old product, and having regard for its life cycle, it's still a good money earner,'' he added. Antibiotics gradually give way to replacements as bacteria become more resistant and companies promote new products. ``I really think the future of the company is the fact that half our sales are (from) products launched less than five years ago,'' he said. Revenue has almost tripled from $25 million in 1995. The company doesn't disclose profits, though Villax said it's always had an operating profit since it started large-scale production in the 1970s. Hungarian Roots ``Hovione is a respected player, with a high-quality image,'' said Enrico Polastro, senior analyst for European pharmaceuticals and fine chemicals at Arthur D. Little Inc.  Villax's father, Ivan Villax, immigrated to Portugal in 1951 and started the company with two other natives of Hungary in 1959. Letters from the founders' names -- Horty, Villax and Onody --were combined for the company name. Ivan Villax's two partners later sold their shares, and he's still the company chairman. ``In the whole of the 60s, we were just a lab in the basement,'' Guy Villax said. ``Occasionally the basement exploded, and the kids were woken up, and that was our momma-and-poppa shop.'' Industrial-scale production began in the 1970s, selling Japanese companies ingredients for use in anti-inflammatory creams and anti-asthma pumps. In the 1980s, as many antibiotics' patents expired, Hovione joined the trend of companies making generic drugs. Right Chemistry The most recent round of growth comes from ``outsourcing'' work, producing pharmaceutical ingredients on behalf of specific drug and biotechnology companies. ``Big Pharma went through a major restructuring, spinning off the chemistry, consolidating,'' Villax said. ``At the same time, you had the emergence of all the biotech sector at Nasdaq, with tremendous amounts of capital to invest in drug discovery. And someone has to do the chemistry.'' Hovione aims to get half its revenue from generic drugs and half from outsourcing work, Villax said. The company's shareholders include Hovione employees, plus some of the chairman's business associates from other ventures, though it has no plans to sell shares in the market, the CEO said. Larger companies have approached Hovione about a possible purchase, he added, though he's skeptical about the benefits for customers, ``and I think that's what matters at the end of the day.'' --Jim Silver in the Lisbon bureau (351-21) 340-4545, or jsilver@bloomberg.net

Press Release
Hovione FarmaCiencia SA is using one of its oldest products to fight the world's newest terrorist threat.

Hovione's Antibiotic Doxycycline Joins Fight Against Anthrax

Nov 05, 2001

A total investment of 120 million MOP (15,6m Euros) duplicates production capacity of the Macau plant.   The inauguration of the expansion of the plant is scheduled for 9th November with the presence of the Chief Executive of Macau SAR, Dr. Edmund Ho.   Inaugurated in 1986, the plant in Macau accounts for one third of the company’s total production.   Exports to the USA, European Community, Japan and Australia. Hovione has almost concluded an investment plan of 120 million MOP (15,6m Euros) for the expansion of its plant in Taipa, Macau. This investment will duplicate the production capacity of Hovione in Macau. This complex will be inaugurated on 9th November by the Chief Executive of Macau SAR, Dr. Edmund Ho. This investment, which began in 2000, demonstrates Hovione’s confidence in the future not only of its plant in Macau but also in the future of the territory. In order to assure future expansion of its activity, Hovione is studying various alternatives for upcoming investments in the Macau territory. Hovione’s plant in Taipa, Macau, began its production of active pharmaceutical ingredients in December 1986 and was approved by the FDA the following year. The plant has today a total workforce of 150 professionals and manufactures Hovione’s most stable process products. The plant in Macau is responsible for one third of Hovione’s total production, and exports to the most demanding markets such as USA, EU, Japan and Australia. Hovione is the Portuguese company that most contributes to health science, investigating and manufacturing with state-of-the-art technology and quality, active pharmaceutical ingredients (APIs) of the last generation. Founded in 1959, Hovione has two synthesis plants, one in Loures (Portugal) and another in Macau, both US FDA (Food and Drug Administration) approved, and a Technology Transfer Center in New Jersey, USA. Hovione began its activity manufacturing generic products, developing in its laboratories proprietary synthetic processes. In the beginning of the 90’s, the company started the second branch of the business subcontracting exclusively to third parties. In the outsourcing business, Hovione develops all the technical services from laboratorial development to the regulatory filing for official approval and commercial manufacture, being today an essential link to the pharmaceutical international companies investigating new drugs. With a professional team of a high scientific level, Hovione distinguishes itself from the competition by the quality of its products and its technical know-how in developing true industrial chemical processes for novel APIs. Among these products stands out the production of active ingredients used in drugs that combat HIV. As the largest R&D investor in the Portuguese pharmaceutical industry, Hovione has already developed more that 100 chemical synthesis processes and filed more than 500 patents all over the world, 400 of which are still effective.

Press Release

Investment of 120 million MOP duplicates Hovione's production capacity in Macau

Nov 05, 2001

Anthrax fear increases sales dramatically Hovione PharmaScience Ltd., with a manufacturing site in Taipa Island, Macau, increased its doxycycline production in order to meet increased demands from US, provoked by the bioterrorists attacks with Anthrax. Together with Bayer’s Ciprofloxacine, the product manufactured by Hovione is an antibiotic specifically approved by the US FDA (Food and Drug Administration) to fight Anthrax in its three forms of infection: cutaneous, gastric or inhaled. This product has more than three decades of commercial activity (which is already a remarkable survival for an antibiotic) Hovione has had a stable production of doxycycline for more than 10 years. In these last three weeks, Hovione received purchase orders similar to 3 times the annual sales to the US. It is enough quantity to treat more than two millions patients, during the 60 days advised treatment. Hovione Macau confirms its engagement in supplying these needs and to assure there will no shortage of doxycycline in the drugstores, either in the US or in any other country. Hovione supplies this product to more than 30 countries, in the Americas, Europe, Australia, and Asia, including Pakistan, India and Iran, being concerned with the supply of pharmaceuticals in accordance to human health needs. An increase in demand has also occurred in the second half of the 90s, with an outbreak of plague in India, and also before the Gulf War. Legislation and flexibility benefits production in Macau In September, ways to supply the foreseen increase in demand after the first strikes, were analyzed and the alterations to the production of the Macau site, the site more suitable to manufacture doxycycline, were authorized. These changes naturally forced a complex re-structuring of our priorities, in order to meet and supply at fast as possible the American market. This task will continue until the end of this year. Accordingly to Carlos Costa, Director of Hovione Macau: “ We have in Macau a more favorable legislation which allows to change rapidly the production plans. In Lisbon, we are obliged to inform the authorities of the nature and quantities of all new products that we are going to manipulate in the future. Well, this only our clients know, we cannot guess.” The European legislation, named EINECS, requires that extensive studies are carried out on any new product which crosses European borders, delaying in many months any investigational project or production line. Similarly, IPPC, which regulates industrial licensing, makes any new industrial project more bureaucratic, slowing the process and hindering its flexibility. The Hovione Macau site began its active pharmaceutical ingredients production in December 1986 and was approved by the FDA the following year. This site today has 150 professionals and manufactures the more stable Hovione products. The Macau factory is responsible for one third of Hovione total production. With a sales volume of 15 million dollars (16,5m Euro), Hovione in Macau will make additional sales of doxycycline corresponding to 4,5 million dollars (5m Euro). Hovione is an international company, which develops and produces with high quality and state-of-the-art technology active pharmaceutical ingredients. Founded in 1959, Hovione has two approved factories by the FDA, in Loures (Portugal) and in Macau, and a Technology Transfer Center in New Jersey (USA). Hovione began its activity with the manufacture of generic products, developing in its R&D laboratories its own chemical synthesis processes. In the 90s, the company developed the second part of the business, with outsourcing to the large pharma and biotech companies. In outsourcing, Hovione develops all technical services, since laboratorial development until the regulatory approval and commercial production, becoming the essential link to the pharmaceutical multinationals that research new medicines. Hovione is the biggest investor in R&D in the Portuguese pharmaceutical industry and already developed more than 100 chemical synthesis process and has more than 500 patents all over the world, of which 400 are still in use.

Press Release

Hovione's factory in Macau supplies antibiotic against anthrax

Oct 31, 2001

Dear Friends, When the organisers of CPhI asked us to write an article about Hovione for the CPhI Show Daily, we accepted but the words that follow are probably not what they expected. Last year we were basking in the sun-shine, it had been a golden time for the fine chemicals industry. The El-dorado was nigh, everyone was investing, the brave ones were buying plants, and some, driven by consultants were spending hundreds of millions of dollars on merging and acquiring other companies. The folly of the stock-market still had everyone in a frenzy. Life seemed sweet, easy and money was plentiful. The bankers in their excitement even decided that those making fine chemicals for the Pharma industry deserved some attention, they organised conferences and issued reports. What a difference 12 months make. We are now in a recession, and the atrocities of September 11th are fresh in our minds. Everywhere one looks, it seems the colours have gone and the World is now in black and white. The articles one reads in the industry magazines talk of over-capacity, slowing growth, withdrawn drugs, unapprovable letters, cancelled projects. In some cases, the extent of the excess-enthusiasm was even given a number: a CHF1.3 billion goodwill charge on acquisition. The fascination with our business will now wane and the wave of interest will go elsewhere. Quite a few of us will remain behind to pick the pieces left behind by this storm, tidy up the house and get it to move forwards. It will take a couple of years to get things back into balance, for the new-comers to find their direction, to establish with clarity who is a quality competitor and who has remained a trusted supplier. Those that expected to grow an API business in 4 or 5 years to $500 million in annual sales will be disappointed; those that have been at it for decades, focusing on compliance and excellence will continue to deliver work that satisfies customers. It is the repeat customer that drives growth; track record is not just the absence of recalls and warning letters, it is also the ability to consistently find solutions for customer problems - and in drug development there are plenty of tough surprises to solve. Being in compliant manufacture is not just a question of dollars; being "cGMP" is not just a question of investment in new facilities. It needs time more than money, it requires having a team of dedicated technical people with many years of accumulated training. You do not "go fast" because of more resources or tougher deadlines; projects move fast well because your technical groups are trained and have done it together many times before, your people are aligned, and the range of skills is well covered and well balanced. Can a confederation of a dozen plants acquired through multiple mergers ever have a common culture, a same view of safety, let alone of quality? How do you manage all the site managers competing for the new project? Being successful in compliant manufacture is tough, it comes with years of nurturing and focus. Is it a surprise that the smaller independent companies do it better than the large giants ? The divide is often the time-scale - some squeeze their people and business partners for their quarterly results, the annual budget takes precedence over customer satisfaction, available capacity is a dreaded cost - others look at available capacity as a positive thing enabling prompt service, and focus on what is in their control: sales in 2003 and 2004 (indeed the sales for the next 2 years were decided some time ago...). The divide is often the choice of target: large companies look at sales and profits, they look at the share price and at how to cut costs, performance is judged on dividends. This is not so for all: some of us are motivated by customers that say thank you, some even compete for, and win, environment awards, but those that succeed, work as partners with their customers to develop new drugs; if they were lucky they started working together 5 year ago for the first 10 kilos; if they are statistically normal, they will have worked together on two failed projects well before they can claim to have put a new drug on the market. Our industry is about saving lives. Though on occasion we are seen as polluters carrying out unsafe operations, and sadly accidents do occur, as in Toulouse only last week. Odd how energetic reactions, deadly reactants, explosives, corrosives and flammables all come together to make pills that cure disease, kill bacteria and destroy viruses. Safety First is not a negotiable item, chemistry and its engineering need competence and have priorities that business pressures must not be allowed to interfere with. Success in this business needs great leadership, the decisions are not easy - Bayer reminded us all how tough it can get. At Hovione we did not participate in the Technicolor storm of the past few years. We had approved a medium term plan in 1994 and executed it with success; in 2000 we approved another medium term plan and we are taking it forward unchanged. It involved buying a field near Princeton to build a kilo lab and pilot plant to support early phase customers in the USA and to assist in the technology transfer to our larger plants when the projects so warrant it. The plan also aims to build additional capacity in our areas of strength: process chemistry, GMP manufacture, injectable grade APIs and corticosteroids. Some of this expansion is taking place in our plant in the Far East which is not encumbered with EINECS costs and speed limitations that slow the pace of drug discovery. The companies that meet at CPhI play a critical role in the world economy. We are a key link in the worldwide health care system - without us the pharmacies would be empty. Ours is an important job, one we can be proud of. It is important that we should move ahead and get on with our business with professionalism, and keep distractions to a minimum. Guy Villax Chief Executive - Hovione

Article
Show Daily CPhI, 9 October 2001

Article published in the CPhI Show Daily Newsletter

Oct 09, 2001

With the commissioning of a 220m2 manufacturing unit dedicated to the synthesis of corticosteroids, Hovione, an independent API manufacturer, widens the range of services offered to the pharmaceutical industry. Totally renovated in 2001 using state-of-the-art technology, the facility was the object of an FDA PAI inspection in June, for which no Form 483 was issued. The plant is suitable for the manufacture of corticosteroids and similar compounds (but not steroids with hormonal activity) under cGMP for oral, topical, inhalation and injectable administration. With controlled personnel access as well as controlled materials flow, the unit produces INDs, NDAs and generic compounds in batches ranging from 1 to 100 kilos. Filtration, drying, milling, sieving, micronization and packing are carried out in 3 distinct class 10.000 clean rooms. Tri-clamped lines to transfer the crystallized reaction mixture into clean room conditions for filtration have been installed for speed and flexibility, allowing also for effective cleaning. Charging of solids is done in a closed circuit preventing contact of the product with the exterior through a high containment solids transfer valve. The site is further equipped with WFI and USP purified water loops. Hovione has 40 years experience in corticosteroid chemistry. The company has expertise in over 75 different analogues and all processes are developed in-house. Hovione´s corticosteroid generic products include betamethasones, beclomethasones, clobetasol, dexamethasone and mometasone. The new facility dedicated to corticosteroids enhances Hovione's capabilities in the development and manufacture of highly regulated multi-step APIs. Another building suitable for high potency compounds and for cytotoxics is currently under evaluation and design. Process equipment Vessels (liters): Glass-lined: 1x 200 – 1x 400 – 1 x 1200 – 1 x 2000 – 1 x 5000 Stainless steel: 2 x 2000 – 1 x 7500 Other: Monoplate filters Static bed dryers Micronization equipment Centrifuge Fluid bed dryers Vacuum tray dryers Sieving and Milling Filter-presses Hovione is an international group dedicated to the synthesis of APIs and serving exclusively the Pharma industry. With FDA inspected plants in Europe and the Far East and sales offices in Hong Kong, Switzerland and New Jersey, Hovione is committed to the highest levels of service and quality. Hovione’s capabilities include process chemistry, worldwide regulatory affairs, kilo to multi-ton manufacture of complex multi-step chemistry of APIs under FDA and ICH cGMP standards.

Press Release

Hovione's new Corticosteroid manufacturing facilities

Oct 08, 2001

An FDA pre-approval inspection took place in Hovione's Loures facility from 31st May to 5th June. Mr. Charles Cote, FDA investigator of the Minneapolis District, stated at the closing meeting that no Form 483 would be issued. Mr. Cote made a general inspection of our quality system, procedures and controls and reviewed in detail the key PAI documentation relating to process validation, cleaning validation, analytical validation, stability testing, batch production and analytical records, raw material approvals. He also reviewed an Annual Product Quality Report for one of our established products, the list of products sent to the U.S. since our last inspection together with the list of complaints and current status. Purified water systems, cleanroom design and controls and microbiological testing were covered as well as a review of analytical and production equipment qualification as part of the inspection of the operational areas. At the closing meeting, Mr. Cote also stated that he was impressed with all of the people with whom he interacted at Hovione. Records were available for all the areas he wished to cover and the Standard Operating Procedures were generally well written. He stated that Hovione had good control over our operations and he thanked our staff for our cooperation with him during the audit. Hovione is an international group dedicated to the synthesis of APIs and serving exclusively the Pharma industry. With FDA inspected plants in Europe and the Far East and sales offices in Hong Kong, Switzerland and New Jersey, Hovione is committed to the highest levells of service and quality. Hovione’s capabilities include process chemistry, worldwide regulatory affairs, kilo to multi-ton manufacture of complex multi-step chemistry of APIs under FDA and ICH cGMP standards.The company also has ISO 9000 certified Quality Management Systems. Hovione was first inspected by the FDA in 1982 and has been successfully inspected regularly ever since. Quality operations at Hovione involve 82 staff, including QA, Regulatory Affairs, QC and the Analytical Group, with dedicated laboratories for Release, In-process Control, Method Development and Validation. The Company is involved in establishing Industry Standards and actively participating in CEFIC/APIC and pharmacopoeial committees. Analytical methods developed in Hovione’s laboratories have been included in pharmacopoeial monographs and the Company regularly supplies EP and USP with substances used as International Reference Standards. Hovione's commitment and investment in the areas of quality, compliance and regulatory issues frequently result in the Company adopting new standards prior to their official implementation. Hovione has filings with every world health authority that has a DMF system for APIs. The Regulatory Group is able to prepare data for an IND, NDA, ANDA, VMF or DMF filed at the FDA, MCA, HPB, TGA, Agence du Médicament, BfArM, or for EP certification.

Press Release

FDA inspection to Hovione site in Loures, Portugal - May 31st to June 5th

Jun 08, 2001

East Windsor Township - Princeton, 2nd March, 2001 – Mayor Janice S. Mironov, East Windsor Township, East Windsor, New Jersey and David Hoffman, President, US Operations, Hovione LLC, Princeton, New Jersey, a wholly owned subsidiary of Hovione SA, are pleased to announce East Windsor Township will be the site of Hovione’s Technology Transfer Center (TTC). The TTC will be located on an 8 acre parcel of land just off exit 8 of the New Jersey Turnpike. The site will consist of commercial offices as well as scale-up and development laboratories. Initial occupancy is scheduled for the 1st Quarter 2001 and will provide employment for 26 people with an expansion capability up to 45. According to Mr. Hoffman, East Windsor Township is an ideal location for technology companies servicing the Pharmaceutical Industry due to the township’s proximity to 9 of the world´s major pharmaceutical companies. The township also has an excellent professional community owing to its centralized location between New York and Philadelphia. According to Mayor Janice S. Mironov, “We are pleased to welcome the US corporate  of an international pharmaceutical active ingredients company such as Hovione to our community. Hovione is an exciting addition to the many firms which have recently located corporate offices and facilities in East Windsor Township, whose superior location and great accessibility were important considerations for these firms”. Hovione will offer process development and scale up services, along with quality control/assurance and regulatory support to the pharmaceutical industry. The technical capability of the TTC will mimic that of Hovione’s fully commercial facilities located in Europe and South China for seamless transition to commercial scale production. The TTC will be fully integrated into Hovione’s global quality network offering US customers real-time data and regulatory support for on-going production in Europe and China. CUH2A, Inc. (Princeton, NJ) has been appointed as the architectural engineering firm and Engineered Technologies Corporation, (Providence, RI) the equipment manufacturer for the TTC. Bids are currently under consideration for the construction and build-out of the facility. Hovione is a global manufacturing company committed to the Pharmaceutical Industry. The principle area of focus is providing specialized technical skills to solve complex problems associated with the development and manufacture of the key active ingredients used in medicines.

Press Release

Hovione locates US Operations in East Windsor Township

Mar 03, 2001

(transcribed and translated at Hovione) The reason for this visit is very simple: It was recently decided by both the Government and all social partners, that we would get together to work with well defined objectives, with a view to significatively improving, here in Portugal, both hygiene, safety at work and our fight against accidents, as well as increasing training and qualification of people at work who create prosperity. It is important to say that on signing the agreement relating to hygiene and safety at work, we assumed that, unfortunately, our Country, is lacking in these fields and, in certain sectors, has an accident rate which is intolerable both from a political and moral point of view relative to the people who work and live in Portugal. It could be thought that these objectives are utopic, but the best way to show that this is not so, is to visit a company that for a long time, and at its own initiative and according to its own strategy, is a centre of excellence. This I take as an example that the Country should know about, not only, but also, in relation to the question of safety. This is the best way to prove to those who do not have this preoccupation sufficiently in mind, what they can and should do and by doing so would not necessarily increase their costs, on the contrary, as has just been mentioned, they could even lower their production costs. Obviously, safety is not exclusively a worry for firms. The State, as regulator and inspector - must recognize that not having done enough in this field is a worry for the firms – but it is also the responsibility of those who work to behave in a matter that safeguards themselves and others. We felt that it was very important that the Country should know Hovione because what is done here in this field is absolutely exemplary and can and should, bearing in mind that natural adaptations required according to the different forms of the country’s economic activity, be copied across the Country, showing that the objectives we have set ourselves, on a country wide scale, are perfectly attainable. Actually, I must refer to another aspect that mentioned here. We have established in our social agreements the right to training. This right, independently from other aspects, assures that all Portuguese workers by 2005 will enjoy 35 hours/year of training. Hovione already offers 70 hours/year training. It is also interesting that training is not something that has been imposed, as a luxury or a political option. In a firm of excellence that assures high standards of technology and is a name in the marketplace, training is an essential component for its own success. At the same time, in this world of constant mutation, it is fundamental to give people the capacity to reply to challenges that are renewed daily as a result of the rapid technological evolution that we live with. But it would be unjust if I did not take advantage of this occasion to state, in the name of the Government, our great appreciation of what Hovione means to Portugal, and not only in what refers to the questions of safety and training. It is a case of quite exemplary capacity for technological innovation and the proof that when we want to, when we really do everything we can and with enormous determination, the conditions exist in Portugal to do as well as anywhere in the world. However, this is not viable without enormous investment, tremendous dedication, effort and competence. I know that several decades ago, Eng. Ivan Villax started in a small laboratory in a cellar. From that small laboratory to what we see here today, there are decades of hard work, of competence, of intelligence which, put to work towards an ideal, assured the building of this enterprise. I feel this is an example to be followed as it demonstrates that it is possible, in Portugal, to achieve the best there is in the World and to have things for which we can be proud from every angle. Such as the matters related to technological capacity, innovation, optimization of management, to all those equally important matters of safety and training in social conscience and of belonging to a community. Many firms tend to function isolated from the community without realizing the importance of being part of it. It is also exemplary that this firm has understood that they can only win by maintaining a constant dialogue with the local community enrichening it at the same time. For all of this, many thanks for this opportunity for the country, more than for myself as I have known of the tradition of excellence that you represent, to grow in self esteem and understand that they too can achieve their own objectives if there is the will and the capacity to do so. Many thanks.

Press Release
on the occasion of his visit to Hovione on 21st February 2001

Speech delivered by Mr. António Guterres, Prime Minister

Feb 21, 2001

This year Hovione celebrates its 40th anniversary in the field of Active Pharmaceutical Ingredient (API) chemistry and, simultaneously, establishes the basis of its strategy for the next millenium. We have chosen this date to mark a milestone in the evolution of the Company, so as to represent the maturity we have attained as we look back over two generations of progressive growth. Celebrating the past and the future, Hovione assesses it’s management system, strategy and image to reflect our experience as well as our technical and scientific competence. Our future success, like our past, will be based on enhancing our API expertise and on meeting the continuous challenges of the Pharmaceutical Industry. Hovione was founded in Portugal in 1959 by a Hungarian chemist, Ivan Villax, who carried out investigation in the field of semi-synthetic tetracyclines and anti-inflammatory corticosteroids. Behind us are 40 years of accumulated API knowledge described in over 100 innovative process chemistry patents. As we continue to focus on the development and production of active pharmaceutical ingredients, the Company feels well positioned to meet the outsourcing needs of the Pharmaceutical Industry. Hovione has carved a niche for itself synthesizing complex APIs which are highly regulated. Our objectives demand the highest standards of professional competency. Combining focused expertise with quality and state-of-the-art technology, Hovione has become an essential provider to Pharmaceutical Companies worldwide. Hovione not only garantees the development of chemical processes and industrial synthesis of APIs, but offers its customers the technical services that include: Lab scale development Optimization and validation of chemical processes at pilot and industrial scale Kilo-lab and pilot-scale regulated production, including clinical supplies Analytical method development and validation Regulatory filings for IND, NDA (DMF or CMC sections) world-wide Manufacturing contracts for tens of kilos to tens of tons Over the past 10 years Hovione’s evolution entered a new phase as a result of our medium term project, I&DEIA XXI, made possible by the availability of European Community funds destined towards the innovation of Portuguese Industry. In 1987 Hovione had worldwide sales of US$14m and employed a staff of 280. Today, after an investment of over US$45m, the Company invoices about US$50m and employs 500 people. During the last decade, Hovione achieved an increased professionalism in market analysis and product development strategy, and evolved from a family orientated concern to a model of professional and global management. Hovione’s business strategy is based on a deeply rooted knowledge of our target markets: the U.S.A., Japan and the EU. Our factory in Macau, established 15 years ago, benefits from its proximity to the People’s Republic of China for the supply of raw materials. Hovione exports 100% of its production to the most demanding markets in the world, half of which are of products launched less than 5 years’ ago. We invest 8% of sales in R&D, 6% in environmental protection and 5% in quality. Our plants are ISO9000 certified and regularly inspected by the US Food and Drug Administration. With 500 staff worldwide, of which a 100 are at the plant in Macau, Hovione is happy and proud to celebrate 40 years of expertise in API chemistry.

Press Release
This year Hovione celebrates its 40th anniversary

40 Years of Expertise in API Chemistry

Jun 01, 1999

Contrast Media is one of two important areas that Hovione defined as key in its 1994 I&DEIA XXI strategic analysis document, the other being offering custom services to the US majors. Hovione is a technology rich company excelling in both difficult chemistry as well as GMP and regulatory affairs. By always tackling the products that others were not interested in because of their difficulty and always taking a pro-active attitude to meeting (instead of avoiding) FDA's increasing severity and tough standards, Hovione is now well equipped to serve the outsourcing needs of the largest US pharmaceuticals companies. Contrast media is an area where no independent manufacturer of bulk existed, the first products to come off patent did so less than 12 months ago, so it was an obvious area where Hovione's skills could be turned into dollars. The surprise was how technically difficult this really was. A team of 60 researchers at Hovione worked non-stop for three years. Contrast media is an area of very high barriers to entry: one needs large capacity (to be a player you need a capacity well in excess of 50 tonnes/year), great technical competence (to meet purity levels of 99.8% and near sterile quality of tonne size batches), know-how and the industrial scale technology to recycle tens of thousands of tonnes of solvents, and last but certainly not least you need to have the ability to prepare tens of kilos of paper meeting every one of FDA's requirements. These products are in many occasions injected, in a single dose, in quantities of 150g. This is the largest parenteral administration of a chemical to a human. Clearly an area only for the most competent and quality generic firms, the market perceives Hovione as such a company.

Press Release

Contrast Media and Custom Services are two key areas in Hovione's strategic analysis document

May 20, 1996

Contact Us

If you would like to learn more about Hovione, kindly fill in the form below and we will be revert to you soon.